Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Depreciation & Amortization (CF) of $2.2 million for Q1 2026, up 37.5% year-over-year from $1.6 million in Q1 2025, and up 4.76% quarter-over-quarter from $2.1 million in Q4 2025.
Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Revolution Medicines' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 37.5% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.0 million (up 29.03% YoY), while the FY2025 annual figure was $7.4 million, up 19.35% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.2 million in Q1 2026, with the low at $901000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $1.4 million (2024), against an average of $1.5 million.
- Peak annual rise in Depreciation & Amortization (CF) reached 50.0% in 2025, while the deepest fall reached 6.25% in 2025.
- Revolution Medicines' Depreciation & Amortization (CF) stood at $1.2 million in 2022, then climbed by 10.88% to $1.3 million in 2023, then increased by 7.28% to $1.4 million in 2024, then jumped by 50.0% to $2.1 million in 2025, then rose by 4.76% to $2.2 million in 2026.
- Business Quant data shows RVMD's Depreciation & Amortization (CF) at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.50 Mn |